Literature DB >> 6293295

Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension.

K Hiramatsu, F Yamagishi, T Kubota, T Yamada.   

Abstract

Ten milligrams nifedipine was administered orally to young and old persons with or without hypertension, and the acute effects of nifedipine on the renin-angiotensin-aldosterone system were studied one half to 3 hours later. Nifedipine reduced blood pressure and increased pulse rate in young and old persons with or without hypertension. Simultaneously, nifedipine produced a significant increase of plasma renin activity in young persons with or without hypertension but failed to do so in old persons with or without hypertension. As a result, angiotensin I and II increased significantly in young persons but not in old persons. Hydralazine elevated aldosterone concentration by stimulating the renin-angiotensin system but nifedipine failed to do so despite its effect on the renin-angiotensin system in young individuals. Since calcium is required to secrete aldosterone, it is suggested that nifedipine blocked aldosterone secretion by the agent's calcium antagonizing action.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293295     DOI: 10.1016/0002-8703(82)90166-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  23 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects.

Authors:  K Handa; T Mori; H Tanaka; Y Takada; A Matsunaga; A Kiyonaga; M Shindo; J Sasaki; K Arakawa
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 5.  The therapeutic dilemma of hypertension in the elderly.

Authors:  S Julius
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Calcium channel blockade: an alternative to diuretic therapy.

Authors:  J P Nicholson; L M Resnick; J Laragh
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

7.  Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension.

Authors:  R Fagard; P Lijnen; E Moerman; J Staessen; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Endocrine physiology of electrolyte metabolism.

Authors:  K G Dawson
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

9.  Effect of nifedipine on plasma catecholamines in man at rest and during exercise.

Authors:  G Defer; Y C Guezennec; F Lhoste
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Nitrendipine and the humoral control of sodium homeostasis.

Authors:  D R Forsyth; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.